Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.7K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

The Journal of experimental medicine·2026
Same author

A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.

Cancer research·2026
Same author

Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients.

Cancers·2025
Same author

Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma.

Cancers·2025
Same author

Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy.

Cancers·2025
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
查看所有相关文章

相关实验视频

Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K

逆转或重新连接血统的可塑性? 从前列腺癌中EZH2损失的教训

Phillip Thienger1, Dilara Akhoundova1,2, Mark A Rubin1,3

  • 1Department for Biomedical Research, University of Bern, Bern, Switzerland.

Cancer research
|February 16, 2026
PubMed
概括
此摘要是机器生成的。

前列腺癌中EZH2的损失并没有逆转血统可塑性,但通过激活KLF转录因子和改变雄激素受体结合,促进了神经内分泌的分化. 这重新连接瘤转录网络,影响治疗策略.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

相关实验视频

Last Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

  • 增强器的凝同源2 (EZH2) 抑制正在探索逆转前列腺癌血统可塑性 (LP) 和复敏瘤对雄激素受体 (AR) 抑制.
  • 前列腺癌的进展涉及向神经内分泌 (NE) 现型的过渡,这一过程受到EZH2.2的影响.

研究的目的:

  • 调查EZH2在前列腺癌进展和过渡到神经内分泌表型中的机制性作用.
  • 阐明EZH2损失如何影响谱系可塑性和转录因子程序.

主要方法:

  • 利用一种基因工程小鼠模型,将前列腺癌的进展归纳为NE表型.
  • 进行了Ezh2的遗传删除,以评估其对LP和NE分化的影响.
  • 分析了转录因子 (TF) 激活,AR的染色体结合景观和基因组位点关联.

主要成果:

  • Ezh2的遗传删除并没有逆转LP,但意外地促进了NE的分化.
  • EZH2的损失激活了KLF转录因子家族成员,促进了转录的多样化.
  • EZH2删除改变了AR染色体结合,将其重定向到KLF相关的基因组部位,从而重塑了AR细胞组.

结论:

  • 前列腺癌中的EZH2损失不仅仅是逆转LP,而是重新连接转录网络并改变AR细胞组.
  • 这些发现完善了对EZH2功能的理解,并对转移性前列腺癌中EZH2抑制剂的临床部署产生影响.
  • 需要进一步的研究来确定使用EZH2抑制来调节瘤谱系动态的最佳策略.